A new study looking at a Type 2 diabetes association alleged by more than 700 Lipitor lawsuit claimants finds that statin users may be at an increased risk for the disease.
According to a report on May 29th from CTVNews.com, patients at risk for strokes and heart attacks may be 15 percent more likely to develop Type 2 diabetes within two years of beginning a high-potency statin treatment, when compared to low-potency statin users. These results may strengthen a Lipitor diabetes link alleged by hundreds of statin claimants.
The research included records from 136,966 patients over 40 in Canada, the United States and the United Kingdom, and was led by the Canadian Network for Observational Drug Side Effect Studies. 20 mg of atorvastatin, a drug marketed as Lipitor, as well as 40 mg of simvastatin, which is also known as Zocor, were considered high-potency treatments, while all others were considered low-potency.
Findings of this study, which were recently published in the British Medical Journal, were met with shock and outrage from users of Lipitor and similar medications.
One patient told CTVNews.com, “To take something I thought was benefiting me and now to find out that it’s actually created even more problems for me, I find that very devastating and very upsetting.”
This research may also come as a surprise to those aware of the American College of Cardiology’s recent push for statins in those at risk for heart attacks and strokes. According to guidelines released in November 2013, doctors should not only consider a person’s “bad” cholesterol levels in assessing whether they should begin taking a statin. They should also factor in age, gender, race, smoking and blood pressure when making the call, according to guidelines.
Authors of the study may disagree with these suggestions. “Following a heart attack or stroke, doctors are more likely to prescribe a high-potency statin, but a lower-strength statin may be a better choice for many patients,” said one of its co-authors.
This may be considered an understatement, given the mounting number of Lipitor lawsuits now filed in the U.S. A Case List updated on May 15th shows 703 claims alleging new-onset diabetes now pending in the U.S. District Court, District of South Carolina. According to claims, Pfizer Inc. failed to adequately warn about Lipitor’s potential to cause Type 2 diabetes in its marketing of the statin.
Contact our Firm to learn more about Lipitor lawsuits, and whether you may be eligible to file a claim over the statin medication. Call us now at .